-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, liver cancer has attracted much attention.
At present, there are two liver cancer immune drug combination therapies approved in China, atelizumab + bevacizumab, and nivolizumab + ipilimumab, which are first-line and second-line drugs, respectively.
Figure 1 Combined therapy of liver cancer immunotherapy
One.
One.
Figure 2 T+A solution significantly prolongs OS
IMbrave150 is an open-label, randomized, parallel-controlled multicenter clinical study for the T+A program.
Figure 3 T+A program significantly prolongs PFS
two.
two.
The patients enrolled in the CheckMate-040 study were advanced HCC intolerance or progression to sorafenib treatment.
three.
three.
B.
four.
four.
Reference materials:
1.
2.
3.
